Cancer therapy comprising a nuclear receptor ligand and a HDAC inhibitor

Details for Australian Patent Application No. 2005221388 (hide)

Owner The University of Birmingham

Inventors Campbell, Moray James; Bunce, Christopher; Peehl, Donna; Gommersall, Lyndon

Agent Griffith Hack

Pub. Number AU-B-2005221388

PCT Pub. Number WO2005/087206

Priority 0405349.2 10.03.04 GB

Filing date 10 March 2005

Wipo publication date 22 September 2005

Acceptance publication date 18 March 2010

International Classifications

A61K 31/203 (2006.01)

A61K 31/167 (2006.01) - having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol

A61K 31/195 (2006.01)

A61K 31/202 (2006.01)

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

28 September 2006 PCT application entered the National Phase

  PCT publication WO2005/087206 Priority application(s): WO2005/087206

18 March 2010 Application Accepted

  Published as AU-B-2005221388

15 July 2010 Standard Patent Sealed

6 October 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005221392-Skipping ropes

2005221383-A dispensing device